vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and TPG RE Finance Trust, Inc. (TRTX). Click either name above to swap in a different company.
Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $35.0M, roughly 1.8× TPG RE Finance Trust, Inc.). TPG RE Finance Trust, Inc. runs the higher net margin — 15.6% vs -70.9%, a 86.6% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs 0.9%). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs -5.1%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
TPG RE Finance Trust, Inc. is a commercial real estate finance firm primarily operating in the United States. It originates, underwrites and manages a portfolio of senior commercial mortgage loans and other real estate-linked debt instruments, serving commercial property owners and investors across multifamily, industrial, office and retail property segments.
CTKB vs TRTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $35.0M |
| Net Profit | $-44.1M | $4.0M |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | 11.6% |
| Net Margin | -70.9% | 15.6% |
| Revenue YoY | 8.1% | 0.9% |
| Net Profit YoY | -557.1% | -62.8% |
| EPS (diluted) | — | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $35.0M | ||
| Q3 25 | $52.3M | $37.8M | ||
| Q2 25 | $45.6M | $36.2M | ||
| Q1 25 | $41.5M | $37.0M | ||
| Q4 24 | $57.5M | $34.7M | ||
| Q3 24 | $51.5M | $40.1M | ||
| Q2 24 | $46.6M | $39.3M | ||
| Q1 24 | $44.9M | $38.9M |
| Q4 25 | $-44.1M | $4.0M | ||
| Q3 25 | $-5.5M | $22.0M | ||
| Q2 25 | $-5.6M | $20.6M | ||
| Q1 25 | $-11.4M | $13.7M | ||
| Q4 24 | $9.6M | $10.7M | ||
| Q3 24 | $941.0K | $22.2M | ||
| Q2 24 | $-10.4M | $24.7M | ||
| Q1 24 | $-6.2M | $16.7M |
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — | ||
| Q1 24 | 51.3% | — |
| Q4 25 | -9.0% | 11.6% | ||
| Q3 25 | -17.6% | 58.4% | ||
| Q2 25 | -23.3% | 57.3% | ||
| Q1 25 | -36.1% | 37.2% | ||
| Q4 24 | 5.2% | 30.3% | ||
| Q3 24 | -8.2% | 55.4% | ||
| Q2 24 | -18.3% | 63.1% | ||
| Q1 24 | -23.9% | 44.0% |
| Q4 25 | -70.9% | 15.6% | ||
| Q3 25 | -10.5% | 58.1% | ||
| Q2 25 | -12.2% | 57.0% | ||
| Q1 25 | -27.5% | 37.0% | ||
| Q4 24 | 16.8% | 43.3% | ||
| Q3 24 | 1.8% | 55.3% | ||
| Q2 24 | -22.4% | 62.9% | ||
| Q1 24 | -13.8% | 43.0% |
| Q4 25 | — | $0.01 | ||
| Q3 25 | — | $0.23 | ||
| Q2 25 | — | $0.21 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $0.09 | ||
| Q3 24 | — | $0.23 | ||
| Q2 24 | — | $0.26 | ||
| Q1 24 | — | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $87.6M |
| Total DebtLower is stronger | — | $3.3B |
| Stockholders' EquityBook value | $341.7M | $1.1B |
| Total Assets | $461.5M | $4.4B |
| Debt / EquityLower = less leverage | — | 3.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $87.6M | ||
| Q3 25 | $93.3M | $93.6M | ||
| Q2 25 | $75.5M | $165.8M | ||
| Q1 25 | $95.3M | $363.0M | ||
| Q4 24 | $98.7M | $190.2M | ||
| Q3 24 | $162.3M | $226.3M | ||
| Q2 24 | $177.9M | $259.2M | ||
| Q1 24 | $168.8M | $203.1M |
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $2.9B | ||
| Q2 25 | — | $3.0B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.7B |
| Q4 25 | $341.7M | $1.1B | ||
| Q3 25 | $378.6M | $1.1B | ||
| Q2 25 | $377.6M | $1.1B | ||
| Q1 25 | $379.6M | $1.1B | ||
| Q4 24 | $395.7M | $1.1B | ||
| Q3 24 | $385.5M | $1.1B | ||
| Q2 24 | $389.1M | $1.1B | ||
| Q1 24 | $392.6M | $1.1B |
| Q4 25 | $461.5M | $4.4B | ||
| Q3 25 | $494.9M | $4.1B | ||
| Q2 25 | $493.3M | $4.2B | ||
| Q1 25 | $482.6M | $4.0B | ||
| Q4 24 | $499.5M | $3.7B | ||
| Q3 24 | $491.2M | $3.7B | ||
| Q2 24 | $483.7M | $3.7B | ||
| Q1 24 | $492.1M | $3.8B |
| Q4 25 | — | 3.10× | ||
| Q3 25 | — | 2.72× | ||
| Q2 25 | — | 2.78× | ||
| Q1 25 | — | 2.56× | ||
| Q4 24 | — | 2.31× | ||
| Q3 24 | — | 2.22× | ||
| Q2 24 | — | 2.25× | ||
| Q1 24 | — | 2.38× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $90.4M |
| Free Cash FlowOCF − Capex | $-1.8M | — |
| FCF MarginFCF / Revenue | -2.9% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | — | 22.73× |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $90.4M | ||
| Q3 25 | $-3.9M | $21.8M | ||
| Q2 25 | $108.0K | $24.7M | ||
| Q1 25 | $-125.0K | $19.1M | ||
| Q4 24 | $2.0M | $112.1M | ||
| Q3 24 | $13.2M | $23.7M | ||
| Q2 24 | $6.2M | $25.6M | ||
| Q1 24 | $4.0M | $37.4M |
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-4.6M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-974.0K | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $12.2M | — | ||
| Q2 24 | $5.2M | — | ||
| Q1 24 | $3.4M | — |
| Q4 25 | -2.9% | — | ||
| Q3 25 | -8.7% | — | ||
| Q2 25 | -3.2% | — | ||
| Q1 25 | -2.3% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 23.7% | — | ||
| Q2 24 | 11.0% | — | ||
| Q1 24 | 7.6% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.3% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | — | 22.73× | ||
| Q3 25 | — | 0.99× | ||
| Q2 25 | — | 1.20× | ||
| Q1 25 | — | 1.39× | ||
| Q4 24 | 0.21× | 10.50× | ||
| Q3 24 | 14.05× | 1.07× | ||
| Q2 24 | — | 1.03× | ||
| Q1 24 | — | 2.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
TRTX
Segment breakdown not available.
